Skip to main content


Welcome to our dedicated page for investor resources. Here you'll find everything you need if you want to invest in pioneering medical science.

Dedicated to solving some of today’s biggest public health challenges, bioMérieux has the focus and the capabilities to discover, develop, and commercialize advanced medical diagnostics solutions that have an impact on people’s lives. We combine the dynamism of a technology-fueled company with the long-term thinking of our founding family. It is this alliance that shapes our strategy and success.

A values-based company, we aim for strong and sustainable performance that benefits our shareholders, our employees, and society.


First-Half 2022 Results


  • €1,658 million in first-half 2022 sales, up 5.3% as published,  stable on a like-for-like basis
  • Q2 sales organic growth up 5.2% like-for-like, led by a strong growth of BIOFIRE® range as well as a good performance in clinical microbiology and industry applications
  • Contributive operating income before non-recurring items reached  €322 million, or 19.4% of sales for the first half of the year
  • 2022 guidance slightly improved
  • bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics
  • Reinforced portfolio of solutions with new product launches 


“bioMérieux achieved a solid performance in the first half of 2022, in line with its expectations, both in terms of top line and profitability. In addition, we made a major acquisition in the field of rapid antimicrobial susceptibility testing with Specific Diagnostics that reinforces our long-standing commitment to sustain antibiotic efficacy for future generations and fits perfectly with our existing solutions. Within a highly uncertain and inflationary environment, we do confirm our annual guidance, slightly adjusted upward. ”

Alexandre Mérieux, Chairman and CEO

URD/Annual Reports

See most comprehensive information about bioMérieux.


Discover our plans to a sustainable future.


Our boards and committees underpin our ability to make decisions and ensure control processes. 

News & publications

bioMérieux combines long-term growth and profitability. Learn more about our performance and activities in our detailed reports and financials.

Analysts coverage & consensus

Financial analysts keep track of our performance. Discover their forecasts here.

Shareholder Area

Already a bioMérieux shareholder or want to start investing?

Regulated Information

To guarantee transparency and sustainability, we abide by a strict set of rules and regulations.